Trial Profile

Treatment of Recurrent Clostridium Difficile Infection With RBX7455: A Dose-ranging, Prospective, Single Center, Open Label Phase I Trial

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jan 2022 According to a Ferring Pharmaceuticals and Rebiotix media release, pooled analysis from the PUNCH CD3 , PUNCH CD3-OLS and NCT02981316 evaluating the Microbiome Health Index for post-Antibiotic dysbiosis (MHI-A) were published in Frontiers in Microbiology.
07 Jan 2022 Results presented in a Ferring Pharmaceuticals and Rebiotix media release.
25 Oct 2020 Results assessing microbial resistome before and after treatment with RBX7455 presented at the IDWeek 2020

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com